A new analy­sis spot­lights the top 20 drugs in the late-stage pipeline

The new cys­tic fi­bro­sis triplet from Ver­tex ranks as the sin­gle most valu­able late-stage ther­a­py in the glob­al pipeline, ac­cord­ing to a new re­port from Van­tage, the ed­i­to­r­i­al arm of Eval­u­ate. And they are way out ahead on the net present val­ue scale used to rank these would-be block­busters.

In this rank­ing, which you can see in full be­low, the Ver­tex triplet in­clud­ing VX-659 has a net present val­ue — or NPV — of $14.4 bil­lion as Phase III da­ta loom, cal­cu­lat­ing costs and po­ten­tial rev­enue.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.